Eylon0.1%+0.025%

Eylon ophthalmic solution is indicated for the short-term symptomatic relief of ocular inflammation accompanied by conjunctival redness (hyperemia), where a corticosteroid is indicated and where the reduction of hyperemia is also desired.

Established / guideline-supported uses

• Acute and chronic allergic (non-infectious) conjunctivitis with significant conjunctival congestion/redness.
• Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe (e.g., allergic conjunctivitis, vernal conjunctivitis, episcleritis) where a mild corticosteroid is appropriate.
• Post-operative inflammation and irritation following ocular surgery, as an adjunct to standard post-operative care.

Not indicated for

Eylon is not indicated for infectious (bacterial, viral, fungal, or mycobacterial) conjunctivitis or keratitis, or for chronic, unsupervised use to simply "whiten" the eyes, since this can mask a more serious underlying condition (see Contraindications).

Each mL of Fluorometholone + Tetrahydrozoline ophthalmic solution contains Fluorometholone 1 mg (0.1% w/v) and Tetrahydrozoline Hydrochloride 0.25 mg (0.025% w/v), in a sterile ophthalmic vehicle with preservative.

Eylon is a fixed-dose ophthalmic (eye drop) combination of two active ingredients that work together to relieve inflamed, red eyes:

• Fluorometholone — a synthetic corticosteroid that reduces ocular inflammation, swelling, and associated discomfort.
• Tetrahydrozoline — a short-acting sympathomimetic (alpha-adrenergic agonist) that constricts superficial conjunctival blood vessels to reduce redness.

Eylon is supplied as a sterile ophthalmic suspension/solution for topical instillation into the eye and is intended for short, physician-directed courses of treatment rather than continuous long-term use.

Ophthalmic corticosteroid–decongestant (vasoconstrictor) combination; Eylon belongs to the class of topical anti-inflammatory eye preparations combined with an ocular decongestant.

Fluorometholone + Tetrahydrozoline combines a corticosteroid with a decongestant, giving it a dual mechanism of action:

Fluorometholone (corticosteroid component)

Fluorometholone inhibits phospholipase A2, thereby suppressing the release of arachidonic acid and downstream inflammatory mediators (prostaglandins, leukotrienes). This reduces capillary permeability, leukocyte infiltration, fibrin deposition, and edema in ocular tissue. Compared with more potent ophthalmic steroids (e.g., dexamethasone, prednisolone), fluorometholone has relatively limited penetration into the anterior chamber, which is associated with a comparatively lower — though not negligible — tendency to raise intraocular pressure (IOP) with short-term use.

Tetrahydrozoline (decongestant component)

Tetrahydrozoline is an imidazoline-derivative, direct-acting alpha-adrenergic agonist. Applied topically, it constricts the small blood vessels of the conjunctiva, producing rapid but temporary whitening of the eye and reducing associated hyperemia.

Together in Fluorometholone + Tetrahydrozoline, these components provide both anti-inflammatory action and cosmetic/symptomatic reduction of redness.

For topical ophthalmic (eye) use only. Instill Eylon into the conjunctival sac using proper aseptic technique; do not inject, ingest, or apply to other body sites. Not for use with contact lenses in place.

No extensive formal drug-interaction studies exist for the fixed combination, but the following are recognized as clinically relevant based on the individual components of Eylon:

• Other topical ophthalmic corticosteroids or NSAID eye drops: concurrent use with Eylon may have additive effects on intraocular pressure; combined corticosteroid use should be avoided unless directed by an ophthalmologist.
• Other topical ocular vasoconstrictors/decongestants: concomitant use with Eylon is not recommended, as it may increase the risk of rebound hyperemia and additive local vasoconstriction.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: although systemic absorption of tetrahydrozoline from topical ophthalmic use is normally minimal, these agents can theoretically potentiate its sympathomimetic (pressor) effects; use Eylon with caution in patients on these medicines.

Reported adverse effects of Eylon include:

Common / local

• Transient burning or stinging on instillation.
• Mild pupillary dilation (mydriasis) with transient blurring of vision.
• Reactive (rebound) conjunctival hyperemia if used too frequently or for too long.

Less common but significant (usually with prolonged use)

• Elevated intraocular pressure/glaucoma.
• Posterior subcapsular cataract formation.
• Delayed corneal/wound healing and, rarely, corneal thinning or perforation.
• Secondary ocular infection (bacterial, viral, or fungal) due to masking of symptoms or local immunosuppression.
• Rarely, systemic sympathomimetic effects (headache, palpitations, elevated blood pressure), particularly with excessive or prolonged use.

There are no adequate and well-controlled studies of Eylon in pregnant women. Although systemic absorption from topical ophthalmic use is expected to be low, Eylon should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

It is not known whether topically applied fluorometholone or tetrahydrozoline are excreted in human breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted before using Eylon while breastfeeding.

Eylon is for topical ophthalmic use only and should not be injected or ingested.

• Intraocular pressure and cataract: Prolonged use of the corticosteroid component of Eylon can result in elevated intraocular pressure/glaucoma, optic nerve damage, and posterior subcapsular cataract formation. Use beyond 7–10 days requires periodic monitoring of intraocular pressure and, where feasible, slit-lamp examination.
• Rebound redness: Frequent or prolonged use of the tetrahydrozoline component can cause rebound (worsening) conjunctival hyperemia. Eylon is not intended for continuous, long-term use beyond the prescribed short course.
• Masking of infection: Corticosteroid use may suppress the clinical signs of infection or may enhance existing ocular infections; use of Eylon in the presence of active corneal or conjunctival infection is not appropriate unless infection is being separately and adequately treated.
• Herpetic keratitis risk: Prolonged corticosteroid use increases the hazard of secondary ocular infection, including reactivation of herpes simplex keratitis; discontinue and seek medical review if eye pain, photophobia, or new visual disturbance develops.
• Thin corneal or scleral tissue: Use with caution in conditions that may cause thinning of the cornea or sclera, where perforation has been reported with topical corticosteroids.
• Do not touch the dropper tip to any surface to avoid contaminating the solution.
• Remove soft contact lenses before use; do not reinsert until advised by the prescriber.
• If no improvement is seen within 7–8 days, or symptoms worsen, stop use and consult a physician.
• Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes mellitus, given the systemic sympathomimetic potential of the tetrahydrozoline component, especially with excessive use.

Topical ophthalmic overdose of Eylon is unlikely to cause serious harm, but excessive or overly frequent instillation may worsen local side effects such as stinging, mydriasis, or rebound redness — rinse the eye with water and contact a physician if this occurs.

Accidental oral ingestion of Eylon, particularly by young children, is a medical emergency: imidazoline decongestants such as tetrahydrozoline can cause serious systemic toxicity (drowsiness, low body temperature, slow heart rate, low blood pressure, and even coma) when swallowed. If ingestion is suspected, seek immediate medical attention or contact emergency services/poison control without delay; do not attempt unsupervised home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use the solution if it has changed color or become cloudy, and discard any remaining product after the period advised on the label/by the pharmacist once opened.

• Pediatric: Safety and efficacy of Eylon have not been established in children under 2 years of age. Use in older children should be under direct medical supervision, as children may be more susceptible to systemic sympathomimetic effects of the tetrahydrozoline component.
• Elderly: No specific dose adjustment is established; because glaucoma and cataract are more prevalent with age, periodic monitoring of intraocular pressure is advisable with use beyond a few days.
• Renal/hepatic impairment: No specific dose adjustment is established for topical ophthalmic use, as systemic absorption is minimal; general precautions still apply.
• Contact lens wearers: Remove soft contact lenses prior to instillation of Eylon; consult the prescriber on when lenses may be reinserted.

Eylon is intended for short-term use, typically guided by the treating physician and generally not exceeding 7–10 days without re-evaluation. Treatment should not be continued or repeated for prolonged, uninterrupted periods without ophthalmologic review, because of the risks of raised intraocular pressure, cataract, and rebound hyperemia with extended use.

Fluorometholone + Tetrahydrozoline is classified as an ophthalmic corticosteroid combined with a topical ocular decongestant (sympathomimetic vasoconstrictor).

Fluorometholone + Tetrahydrozoline acts through two complementary mechanisms: fluorometholone suppresses the inflammatory cascade by inhibiting phospholipase A2 and reducing prostaglandin/leukotriene production, capillary permeability, and leukocyte migration in ocular tissues; tetrahydrozoline directly stimulates alpha-adrenergic receptors on conjunctival vascular smooth muscle, producing local vasoconstriction that reduces visible redness and associated congestion.

Safety and efficacy of Eylon have not been established in children under 2 years of age. In children 2 years and older, Eylon should be used only under the direct supervision of a physician, at the lowest effective dose and frequency, due to the potential for systemic sympathomimetic effects and corticosteroid-related ocular effects with prolonged use.